{'52WeekChange': -0.30926275,
 'SandP52WeekChange': None,
 'address1': '700 Park Offices Drive',
 'address2': 'Suite 200',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 17.92,
 'askSize': 3200,
 'averageDailyVolume10Day': 445737,
 'averageVolume': 559487,
 'averageVolume10days': 445737,
 'beta': 2.316578,
 'beta3Year': None,
 'bid': 17.25,
 'bidSize': 1800,
 'bookValue': 6.08,
 'category': None,
 'circulatingSupply': None,
 'city': 'Research Triangle Park',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 18.205,
 'dayLow': 17.27,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -3.19,
 'enterpriseToRevenue': None,
 'enterpriseValue': 429188544,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '919 741 5830',
 'fiftyDayAverage': 20.881857,
 'fiftyTwoWeekHigh': 41.8,
 'fiftyTwoWeekLow': 8.8,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 28627485,
 'forwardEps': -4.33,
 'forwardPE': -4.0508084,
 'fromCurrency': None,
 'fullTimeEmployees': 104,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.10651,
 'heldPercentInstitutions': 0.97396004,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/g1therapeutics.com',
 'longBusinessSummary': 'G1 Therapeutics, Inc., a clinical-stage '
                        'biopharmaceutical company, engages in the discovery, '
                        'development, and commercialization of small molecule '
                        'therapeutics for the treatment of patients with '
                        'cancer. It is developing trilaciclib, an intravenous '
                        'cyclin-dependent kinases (CDK) 4/6 inhibitor that is '
                        'in Phase 1b/2 clinical trials for patients with '
                        'extensive-stage small cell lung cancer(SCLC), as well '
                        'as Phase 2 clinical trial for patients with '
                        'first-line (SCLC) and metastatic triple-negative '
                        'breast cancer; lerociclib, an oral CDK4/6 inhibitor '
                        'that is in Phase 1b/2a clinical trials for the '
                        'treatment of breast cancer and in Phase 1b clinical '
                        'trial for non-small cell lung cancer; and '
                        'rintodestrant, an oral selective estrogen receptor '
                        'degrader, which is in Phase I/2 clinical trial. G1 '
                        'Therapeutics, Inc. has a collaboration with Quantum '
                        'Leap Healthcare Collaborative to evaluate trilaciclib '
                        'for neoadjuvant treatment of locally advanced breast '
                        'cancer. The company was founded in 2008 and is '
                        'headquartered in Research Triangle Park, North '
                        'Carolina.',
 'longName': 'G1 Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 661912256,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_141112421',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -129518000,
 'nextFiscalYearEnd': 1640908800,
 'open': 18.11,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '919 213 9835',
 'previousClose': 18.27,
 'priceHint': 2,
 'priceToBook': 2.8848686,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 18.205,
 'regularMarketDayLow': 17.27,
 'regularMarketOpen': 18.11,
 'regularMarketPreviousClose': 18.27,
 'regularMarketPrice': 18.11,
 'regularMarketVolume': 442025,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 37737300,
 'sharesPercentSharesOut': 0.0834,
 'sharesShort': 3148870,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 3059400,
 'shortName': 'G1 Therapeutics, Inc.',
 'shortPercentOfFloat': 0.137,
 'shortRatio': 5.15,
 'startDate': None,
 'state': 'NC',
 'strikePrice': None,
 'symbol': 'GTHX',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -3.448,
 'twoHundredDayAverage': 17.71349,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'bd84c3e0-0dae-33f1-b209-a61564837b23',
 'volume': 442025,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.g1therapeutics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '27709'}